| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Hospital & Healthcare Services
|
Compare with Industry peers |
| Website | http://www.choksilab.com | |
| Market Cap | 30.20 Cr. | |
| Enterprise Value(EV) | 64.38 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 3.53 | Trailing Twelve Months Ending 2022-12 |
| Price-Earning Ratio (PE) | 12.27 | Trailing Twelve Months Ending 2022-12 |
| Industry PE | 48.28 | Trailing Twelve Months Ending 2022-12 |
| Book Value / Share | 25.99 | Trailing Twelve Months Ending 2022-12 |
| Price to Book Value | 1.67 | Calculated using Price: 43.36 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 0.70 Cr. | 6,965,263 Shares |
| FaceValue | 10 | |
| About Choksi Laboratories Ltd. | ||
| Established in 1982, Choksi Laboratories Limited (CLL), is more widely known as a leading analysis and research group, providing complete solutions for improving quality in processes, products and services. | ||
| 1 Day |
|
+3.24% |
| 1 Week |
|
+3.14% |
| 1 Month |
|
+1.55% |
| 3 Month |
|
+16.25% |
| 6 Month |
|
+17.83% |
| 1 Year |
|
+51.34% |
| 2 Year |
|
+270.60% |
| 5 Year |
|
+87.30% |
| 10 Year |
|
+581.76% |
| 9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | 5.95 | 4.45 | 3.67 | 4.34 | 6.19 | 6.90 | -17.57 | -13.74 | 1.16 | |
| Return on Capital Employed (%) | 9.42 | 9.39 | 7.32 | 8.41 | 10.49 | 10.14 | -8.27 | 0.02 | 6.75 | |
| Return on Assets (%) | 3.19 | 2.31 | 1.80 | 2.15 | 3.16 | 3.20 | -6.53 | -4.06 | 0.32 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 20 | 19 | 20 | 21 | 22 | 24 | 20 | 18 | 18 | 18 | |
| Non Curr. Liab. | 8 | 6 | 9 | 5 | 7 | 18 | 29 | 31 | 30 | 29 | |
| Curr. Liab. | 10 | 12 | 14 | 14 | 16 | 13 | 14 | 16 | 16 | 15 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 39 | 38 | 43 | 41 | 45 | 55 | 64 | 65 | 63 | 62 | |
| Non Curr. Assets | 27 | 23 | 28 | 28 | 30 | 39 | 47 | 52 | 49 | 48 | |
| Curr. Assets | 11 | 15 | 15 | 13 | 15 | 16 | 17 | 13 | 14 | 14 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 39 | 38 | 43 | 41 | 45 | 55 | 64 | 65 | 63 | 62 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
| Net Sales | 20 | 22 | 22 | 29 | 31 | 34 | 28 | 26 | 30 | 35 | |
| Other Income | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total Income | 20 | 23 | 22 | 30 | 32 | 34 | 28 | 26 | 30 | 35 | |
| Total Expenditure | -16 | -17 | -17 | -24 | -25 | -26 | -25 | -22 | -21 | -23 | |
| PBIDT | 4 | 6 | 5 | 6 | 7 | 8 | 3 | 5 | 9 | 12 | |
| Interest | -1 | -2 | -1 | -1 | -2 | -2 | -2 | -3 | -3 | -3 | |
| Depreciation | -2 | -3 | -3 | -3 | -3 | -4 | -5 | -5 | -5 | -5 | |
| Taxation | 0 | -1 | 0 | 0 | -1 | -1 | 2 | 0 | 0 | -1 | |
| Exceptional Items | -2 | ||||||||||
| PAT | 1 | 1 | 1 | 1 | 1 | 2 | -4 | -3 | 0 | 2 | |
| Adjusted EPS | 2 | 1 | 1 | 1 | 2 | 2 | -6 | -4 | 0 | 4 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 2 | 4 | 2 | 7 | 7 | 6 | 7 | 3 | 6 | 8 | |
| Cash Fr. Inv. | -3 | -6 | -1 | -7 | -2 | -5 | -10 | -14 | -8 | -3 | |
| Cash Fr. Finan. | 0 | 1 | -1 | 1 | -5 | -1 | 2 | 11 | 2 | -5 | |
| Net Change | 0 | -1 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | |
| Cash & Cash Eqvt | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
|
Mon, 29 May 2023
Approved And Taken On Record 'Audited Standalone Financial Results' For The Fourth Quarter And Year Ended On 31St March 2022. 1. Approved and taken on record Audited Standalone Financial Results for the Fourth quarter and year ended on 31st March 2023 along with the Auditors Report pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 and Declaration in respect of Unmodified opinion under Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015. 2. Approved the appointment of M/s Tannmay V. Rajkumar & Co. as Internal Auditor of the Company for the Financial year 2022-23;3. Noting of Letter received form Mr. Ratnesh Sadoriya for showing his interest not to re-appoint him as Independent Director; |
|
Mon, 29 May 2023
Approved And Taken On Record 'Audited Standalone Financial Results' For The Fourth Quarter And Year Ended On 31St March 2022. 1. Approved and taken on record Audited Standalone Financial Results for the Fourth quarter and year ended on 31st March 2023 along with the Auditors Report pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 and Declaration in respect of Unmodified opinion under Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015. 2. Approved the appointment of M/s Tannmay V. Rajkumar & Co. as Internal Auditor of the Company for the Financial year 2022-23;3. Noting of Letter received form Mr. Ratnesh Sadoriya for showing his interest not to re-appoint him as Independent Director; |
|
Mon, 29 May 2023
Announcement under Regulation 30 (LODR)-Change in Management Pursuant to regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 We Wish to inform you that Company has received the Letter form Mr. Ratnesh Sadoriya for showing his interest not to re-appoint him as Independent Director. |
| Mon, 29 May 2023 |
Close Crossing Last Month Close From Below
|
Opening at Low
|
Closing Above Previous High
|
High Increase in 3 Months
|
High Increase in 1 Year
|
Equities
M.F.
Sectors
StockEdge Social